1. Poirey S, Polge A, Bertinchant JP, Bancel E, Boyer JC, Fabbro-Peray P, et al. CK-MB mass test in ischemic myocardial injury. Comparison of two tests: BioMerieuxVidas and sanofi access immunoassays. J Clin Lab Anal. 2000; 14:43–47. PMID:
10683612.
2. Fahie-Wilson MN, Burrows S, Lawson GJ, Gordon T, Wong W, Dasgupta B. Prevalence of increased serum creatine kinase activity due to macro-creatine kinase and experience of screening programmes in district general hospitals. Ann Clin Biochem. 2007; 44:377–383. PMID:
17594785.
Article
3. Serdar MA, Tokgoz S, Metinyurt G, Tapan S, Erinç K, Haşimi A, et al. Effect of macro-creatine kinase and increased creatine kinase BB on the rapid diagnosis of patients with suspected acute myocardial infarction in the emergency department. Mil Med. 2005; 170:648–652. PMID:
16173202.
Article
4. Schulenburg D, De Lange W, Van Jaarsveld H, Kuyl JM. Persistently elevated CKMB and negative troponin T in a patient at ischaemic risk with chest pain. Cardiovasc J Afr. 2010; 21:47–48.
5. Liu CY, Lai YC, Wu YC, Tzeng CH, Lee SD. Macroenzyme creatine kinase in the era of modern laboratory medicine. J Chin Med Assoc. 2010; 73:35–39.
Article
6. Lee KN, Csako G, Bernhardt P, Elin RJ. Relevance of macro creatine kinase type 1 and type 2 isoenzymes to laboratory and clinical data. Clin Chem. 1994; 40:1278–1283.
Article